Search research articles
Contact Us
Filters
Showing results (511-520 of 532) with videos related to
Page
of 54
Sort By:
Annals of Surgical Oncology
|
November 20, 2016
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40
Harry D Bear, Gong Tang, Priya Rastogi, et al.
Journal of the National Cancer Institute
|
March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
Rim S Kim, Nan Song, Patrick G Gavin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 16, 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer
R Dent, F André, A Gonçalves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2017
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
Joanne L Blum, Patrick J Flynn, Greg Yothers, et al.
Ecancermedicalscience
|
June 17, 2014
Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014)
Michael Ewer, Luca Gianni, Fabrizio Pane, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
February 16, 2025
Patient Selection and Outcomes in Reirradiation for Head and Neck Cancers: A Prospective Cohort Study
S Ghosh Laskar, A Kumar, R Salunkhe, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Communications
|
March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
The New England Journal of Medicine
|
October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H Romond, Edith A Perez, John Bryant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 21, 2013
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies
Matthew J Brauer, Guanglei Zhuang, Maike Schmidt, et al.
Page
of 54
Search research articles
Search
Showing results (511-520 of 532) with videos related to
Sort By:
Page
of 54
Annals of Surgical Oncology
|
November 20, 2016
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40
Harry D Bear, Gong Tang, Priya Rastogi, et al.
Journal of the National Cancer Institute
|
March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
Rim S Kim, Nan Song, Patrick G Gavin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 16, 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer
R Dent, F André, A Gonçalves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2017
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
Joanne L Blum, Patrick J Flynn, Greg Yothers, et al.
Ecancermedicalscience
|
June 17, 2014
Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014)
Michael Ewer, Luca Gianni, Fabrizio Pane, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
February 16, 2025
Patient Selection and Outcomes in Reirradiation for Head and Neck Cancers: A Prospective Cohort Study
S Ghosh Laskar, A Kumar, R Salunkhe, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Communications
|
March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
The New England Journal of Medicine
|
October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H Romond, Edith A Perez, John Bryant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 21, 2013
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies
Matthew J Brauer, Guanglei Zhuang, Maike Schmidt, et al.
Page
of 54